Gammacan International Inc - Current report filing (8-K)
October 05 2007 - 5:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
October 1, 2007
(Date of Earliest Event Reported)
GAMMACAN INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
0-32835
|
33-0956433
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
39 Jerusalem St.
Kiryat Ono 55423 Israel
(Address of principal executive offices)
(972) (3) 738-2616
(Registrants telephone number, including area code)
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
1.01
Entry
into a Material Definitive Agreement
On
October 1, 2007, the registrant issued a press release announcing the registrant
entered into an Agreement for the Purchase and Sale of Blood Plasma with
DCI Management Group, LLC (
DCI
) (the
Plasma
Agreement
). A copy of the press release making
such an announcement is found in Exhibit 99.1 hereto.
Under
the terms of the Plasma Agreement, DCI will collect plasma from Vitiligo
donors at DCI operated FDA-approved, IQPP certified donor centers for the
manufacture of VitiGam, the registrants lead product in development
for the treatment of Stage III and IV melanoma. The entry into this agreement
is part of the registrants revised strategy to assure a continued and
uninterrupted supply of Vitiligo plasma for the clinical development and
long-term commercial sale of VitiGam as the registrant gears up to
submit an Investigational New Drug Application for VitiGam which
it anticipates submitting by the end of year end 2007.
The foregoing description of the Plasma Agreement is qualified in its entirety by the Plasma Agreement which is found in Exhibit 10.1 hereto.
Item
8.01
Other Events
As
part of this revised strategy, the registrant also announced in the press
release the amendment of its current plasma supply agreement with
Life Therapeutics from exclusive to non-exclusive.
Item
9.01 Financial Statements and Exhibits
|
10.1
|
Agreement for the Purchase and Sale of Blood Plasma*
|
|
99.1
|
Press Release dated October 1, 2007
|
*
The
registrant has requested confidential treatment with respect to this exhibit.
In the event that the Securities and Exchange Commission should deny such
request in whole or in part, such exhibit or the relevant portions thereof
shall be filed by amendment to this Current Report on Form 8-K.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: October 5
,
2007
|
GAMMACAN INTERNATIONAL, INC.
|
|
|
|
By:
/s/ Patrick Schnegelsberg
|
|
Name: Patrick
N.J. Schnegelsberg
|
|
Title: Chief
Executive Officer
|
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Sep 2023 to Sep 2024